Enterprise Value
1.334B
Cash
75.64M
Avg Qtr Burn
-10.28M
Short % of Float
25.26%
Insider Ownership
52.41%
Institutional Own.
23.58%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NGENLA® Somatrogon Details Pediatric growth hormone deficiency | Approved Quarterly sales | |
Rayaldee (calcifediol ER capsules) Details Chronic kidney disease | Approved Quarterly sales | |
OPK88003 (oxyntomodulin analog) (GLP-1R/GCGR agonist) Details Type 2 diabetes | Phase 2 Update | |
SAR441236 Details Human immunodeficiency virus | Phase 1 Update | |
MDX2001 (Tetraspecific LASER) Details Cancer, Solid tumor/s | Phase 1 Initiation | |
Rayaldee Details COVID-19 | Failed Discontinued |